H
Jul 23 at 09:55 AM
๐ข ๐๐จ๐ฆ๐ง ๐๐ก: Eli Lilly Delays Retatrutide Approval Filing to Q1 2027 - $Eli Lilly(LLY.US) $Hims & Hers Health(HIMS.US) $Novo Nordisk AS(NVO.US)
๐ ๐๐ฒ๐ ๐๐ถ๐ด๐ต๐น๐ถ๐ด๐ต๐๐:โค ๐๐น๐ถ ๐๐ถ๐น๐น๐ plans to file for ๐ฟ๐ฒ๐๐ฎ๐๐ฟ๐๐๐ถ๐ฑ๐ฒ approval in ๐ค๐ญ ๐ฎ๐ฌ๐ฎ๐ณ.โค Filing delayed to gather additional ๐บ๐ฎ๐ป๐๐ณ๐ฎ๐ฐ๐๐๐ฟ๐ถ๐ป๐ด and quality-control data.โค Phase 3 trials met primary endpoints in two additional studies.โค Adults with obesity and Type 2 diabetes lost up to ๐ฎ๐ป ๐ฎ๐๐ฒ๐ฟ๐ฎ๐ด๐ฒ ๐ผ๐ณ ๐ฎ๐ฌ.๐ด% body weight.โค Adults with severe obesity and cardiovascular disease lost up to ๐ฎ๐ป ๐ฎ๐๐ฒ๐ฟ๐ฎ๐ด๐ฒ ๐ผ๐ณ ๐ฎ๐ฎ.๐ฒ% body weight.โค Retatrutide targets ๐๐๐ฃ-๐ญ, ๐๐๐ฃ, and ๐ด๐น๐๐ฐ๐ฎ๐ด๐ผ๐ป hormones.โค Common side effects included ๐ฑ๐ถ๐ฎ๐ฟ๐ฟ๐ต๐ฒ๐ฎ, ๐ป๐ฎ๐๐๐ฒ๐ฎ, and ๐ฐ๐ผ๐ป๐๐๐ถ๐ฝ๐ฎ๐๐ถ๐ผ๐ป.โค TD Cowen estimates retatrutide could generate $๐ฏ.๐ด ๐ฏ๐ถ๐น๐น๐ถ๐ผ๐ป in ๐ฎ๐ฌ๐ฏ๐ฌ sales.โค Novo Nordisk recently sued Lilly over ๐ฎ๐น๐น๐ฒ๐ด๐ฒ๐ฑ false advertising claims.๐ ๐๐ ๐ฝ๐ฒ๐ฟ๐ ๐ฆ๐๐ฎ๐๐ฒ๐บ๐ฒ๐ป๐:๐๐ฒ๐ป๐ป๐ฒ๐๐ต ๐๐๐๐๐ฒ๐ฟ, President of Lilly Cardiometabolic Health:"We believe we have the information necessary to file for approval globally for retatrutide as a potential treatment for obesity, knee osteoarthritis pain and obstructive sleep apnea."
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.